Sat.Jun 03, 2023 - Fri.Jun 09, 2023

article thumbnail

ASCO: J&J, Legend's Carvykti stages stellar show in earlier myeloma. But has the CAR-T reached a ceiling?

Fierce Pharma

After a recent data leak reveale | After a recent data leak revealed a dramatic benefit for J&J and Legend’s Carvykti in earlier treatment of multiple myeloma, the pair has peeled back some even more stunning efficacy results that could further pressure Bristol Myers Squibb’s rival CAR-T therapy, Abecma.

99
article thumbnail

Ketamine Can Treat Depression as Effectively as Electroconvulsive Therapy

AuroBlog - Aurous Healthcare Clinical Trials blog

The “dissociative anesthetic” ketamine looks ever more promising as a safe and effective treatment for intractable depression. A new randomized trial from researchers in the United States has shown that injections of ketamine are at least as effective as electroconvulsive therapy (ECT) when treating non-psychotic forms of major depression.

Trials 237
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

This Pill Can Halve The Risk of Death After Lung Cancer, Scientists Say

AuroBlog - Aurous Healthcare Clinical Trials blog

A pill has been shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumor, according to clinical trial results presented on Sunday.

Scientist 222
article thumbnail

Biogen scraps late-stage study for Parkinson’s drug

Bio Pharma Dive

The biotech, which has trimmed various research programs over the past year, cited the trial’s complexity and long timeline as reasons for its discontinuation.

Drugs 262
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Cybersecurity in pharma: Securing the future

Pharmaceutical Technology

Earlier this year, Sun Pharmaceutical Industries , one of India’s largest generic drug producers, reported a major cybersecurity breach , impacting its business operations. A ransomware group later claimed responsibility for the incident, which was one of several high-profile cybersecurity breaches in India over the past three years. Pharma companies around the world have also faced similar threats , some of which have impacted national security and public health.

Genomics 276
article thumbnail

After years of disappointment, cancer vaccines show new promise

Bio Pharma Dive

Moderna presented new data at ASCO for its melanoma shot, highlighting progress with a personalized approach that’s also being pursued by BioNTech and Gritstone.

Vaccine 331

More Trending

article thumbnail

Avadel Pharmaceuticals launches excessive daytime sleepiness therapy in US

Pharmaceutical Technology

Avadel Pharmaceuticals has introduced LUMRYZ (sodium oxybate) for commercial use in the US to treat cataplexy (excessive daytime sleepiness, or EDS) in adult patients with narcolepsy. LUMRYZ is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime. The US Food and Drug Administration (FDA) granted final approval to the therapy in May 2023.

Pharmacy 246
article thumbnail

ASCO: AstraZeneca, Daiichi's Enhertu delivers 'very compelling' pan-tumor activity, experts say

Fierce Pharma

AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. | AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. Now, the companies are positioning the HER2 antibody-drug conjugate for expansion into other tumor types with data that researchers view as very compelling.

Antibody 133
article thumbnail

Upstream Bio raises $200M in fresh funding for asthma drug

Bio Pharma Dive

The biotech’s experimental drug, currently in Phase 1 testing, has drawn investor attention despite a difficult funding environment for drug startups.

Drugs 173
article thumbnail

Dr K Sujith Kumar appointed as new drug controller-in-charge in Kerala

AuroBlog - Aurous Healthcare Clinical Trials blog

Dr K Sujith Kumar, the senior deputy drugs controller (DDC) at the department of drugs control administration (DCA) in Kerala has been appointed as the drug controller-in-charge of the state from Thursday, June, 1. A Ph D holder in Pharmaceutical Regulatory Affairs (PRA) from the JSS University in Mysore, Dr.

Drugs 245
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Alkeus raises funds to launch Stargardt disease therapy gildeuretinol

Pharmaceutical Technology

Alkeus Pharmaceuticals has raised $150m in Series B financing to support the registration and launch of gildeuretinol (ALK-001) to treat Stargardt disease, a genetic cause of blindness in children and young adults. Led by Bain Capital Life Sciences, the financing round has also seen participation from Sofinnova Investments, TCGX and Wellington Management.

Genetics 279
article thumbnail

Eisai, Biogen's Alzheimer's disease drug Leqembi passes muster at FDA adcomm

Fierce Pharma

After a daylong discussion among experts on an FDA advisory committee, Eisai and Biogen's Leqembi is heading into the final stretch of its regulatory review on strong footing. | After a daylong discussion among experts on an FDA advisory committee, Eisai and Biogen's Leqembi is heading into the final stretch of its regulatory review on strong footing.

Drugs 144
article thumbnail

J&J sees trial data supporting earlier CAR-T use in multiple myeloma

Bio Pharma Dive

The results, which partially leaked in April, show Carvykti’s potential to be used after a drug called Revlimid fails, rather than reserved for only after several treatments do.

Trials 351
article thumbnail

This Common Artificial Sweetener Can Break Down DNA, Scientists Warn

AuroBlog - Aurous Healthcare Clinical Trials blog

The artificial sweetener sucralose (marketed as Splenda) is widely used and found in products like diet soda and chewing gum. According to a new study, it’s also capable of damaging the DNA material inside our cells.

DNA 240
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

China grants EUA to Covid-19 vaccine against XBB descendent lineages

Pharmaceutical Technology

WestVac Biopharma has announced that the Chinese authorities have granted emergency use authorisation (EUA) for coviccine trivalent XBB.1.5-recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta) protein vaccine (Sf9 cell). This marks the world’s first Covid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2. The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University.

Vaccine 269
article thumbnail

After Merck's flashpoint IRA lawsuit, Biogen CEO and others register their own complaints

Fierce Pharma

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). | Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. At the BIO International Convention, Biogen CEO Chris Viehbacher registered severe criticism of the IRA and said his company was considering filing its own lawsuit.

Drugs 131
article thumbnail

FDA sets decision dates for Vertex, CRISPR gene editing drug

Bio Pharma Dive

The regulator will issue separate verdicts on the pioneering treatment’s use in sickle cell disease and beta thalassemia, with the first expected late this year.

article thumbnail

Antidepressant Psychedelics With No Hallucinations May Finally Be Possibl

AuroBlog - Aurous Healthcare Clinical Trials blog

Researchers have recently shown that separate mechanisms drive the hallucinogenic and antidepressant effects of psychedelics like LSD and psilocin, potentially paving the way to use these ‘party drugs’ as treatments that don’t trigger psychedelic trips.

Research 237
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Leading innovators in transcription factors for AAV for the pharmaceutical industry

Pharmaceutical Technology

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on on Innovation in Pharmaceuticals: Transcription facto

Gene 262
article thumbnail

June 8, 2023: LTC Data Cooperative Releases Funding Opportunity for 2023 Real World Data Scholars Program

Rethinking Clinical Trials

The Long-Term Care (LTC) Data Cooperative this week announced a request for applications for the newly established 2023 Real World Data Scholars Program. This program supports the development of advanced graduate students, postdoctoral fellows, and early-career faculty who are interested in developing their expertise and experience in working with electronic health record (EHR) data.

article thumbnail

FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug

Bio Pharma Dive

In a 6-0 vote, a group of independent advisers agreed recent clinical trial data confirmed the drug’s benefit, paving the way for an FDA decision early next month.

Drugs 324
article thumbnail

Indian hospitals set their sights on green healthcare infrastructure to improve patient recovery

AuroBlog - Aurous Healthcare Clinical Trials blog

Indian hospitals have now set their sights on green healthcare infrastructure in an effort to improve patient recovery while making use of natural resources in an efficient and environment-friendly manner. According to Ravideep Singh, associate director, Creative Designer Architects, designing sustainable healthcare infrastructure is gaining traction.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Deal of the week: Strive Health raises $166m to aid kidney health services

Pharmaceutical Technology

Each week, Pharmaceutical Technology’s editors select a deal that illustrates the themes driving change in our sector. The deal may not always be the largest in value, or the highest profile. But it will tell us where the leading companies are focusing their efforts, and why. This new, thematic deal coverage is driven by our underlying Disruptor data which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors.

Marketing 259
article thumbnail

June 7, 2023: This Week’s PCT Grand Rounds Will Feature the DUPLICATE Initiative

Rethinking Clinical Trials

Dr. Shirley Wang In this Friday’s PCT Grand Rounds, Shirley Wang of Harvard Medical School will present “Emulating Randomized Clinical Trials With Non-randomized Real-World Evidence Studies: Results From the RCT DUPLICATE Initiative.” The Grand Rounds session will be held on Friday, June 9, 2023, at 1:00 pm eastern. The DUPLICATE initiative is building an empirical evidence base for using longitudinal insurance claims prospectively to achieve large-scale replication of randomiz

article thumbnail

Medicare sets next tranche of drugs to face price hike penalties

Bio Pharma Dive

CMS named 43 Part B drugs for which prices rose more than inflation, and which will have lower coinsurance rates next quarter as a result.

Drugs 305
article thumbnail

Need to amend Schedule P of D&C Act to include stringent norms on disposal of unused & expired medicines

AuroBlog - Aurous Healthcare Clinical Trials blog

There is a growing concern about the lack of stringent norms on disposal of unused and expired medicines that pose a threat to health and the environment. The key issue is the lack of dedicated guidelines on the disposal under the Drugs & Cosmetics Act.

Medicine 175
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA grants orphan drug designation to DTx Pharma’s CMT1A therapeutic

Pharmaceutical Technology

The US Food Drug Administration (FDA) has granted orphan drug designation to DTx Pharma’s investigational DTx-1252 for the treatment of Charcot-Marie-Tooth disease Type 1A (CMT1A). DTx-1252 is a fatty acid ligand conjugated oligonucleotides (FALCON) small interfering RNA (siRNA) therapeutic which represses the PMP22 gene in Schwann cells. It induces remyelination of axons to normal levels, increases muscle coordination, agility, mass, grip and strength, and improves electrophysiological measurem

Drugs 246
article thumbnail

June 6, 2023: INSPIRE Demonstration Project Principal Investigators Share Update at Annual Steering Committee Meeting

Rethinking Clinical Trials

In an interview at the annual NIH Pragmatic Trials Collaboratory Steering Committee meeting in Bethesda, Maryland, Richard Platt, MD, MS (co-principal investigator) and Shruti Gohil, MD, MPH (lead investigator) of the INSPIRE Demonstration Project , shared the status of the trials, discussed recent lessons learned, described the impact they hope their trials will have on the future of healthcare, and reflected on the impact the NIH Collaboratory has had on their trials thus far.

Trials 130
article thumbnail

Using twin viruses, startup AAVantgarde aims to extend gene therapy’s reach

Bio Pharma Dive

The biotech has raised about $65 million to test two ways to deliver larger genes into the body, each of which could help gene therapy treat more diseases.

Gene 264
article thumbnail

The Facilitation and Benefits of Clinical Studies with Home Visits for Patients

Deltaclinical

Clinical trials are an indispensable part of medical research, testing new treatments and pharmaceuticals to improve health care. Traditionally, these studies were conducted in medical facilities, but today clinical studies with home visits are becoming increasingly popular. In this blog post, we will explore the benefits of clinical trials with home visits from the patient’s perspective. 1.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.